Rockefeller Capital Management
CVKD icon

Rockefeller Capital Management’s Cadrenal Therapeutics CVKD Stock Holding History

Rockefeller Capital Management’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$501 Hold
150
– – ﹤0.01% 4599
2026
Q1 		$768 Sell
150
-150
-50% -$1.05K ﹤0.01% 4522
2025
Q4 		$2.03K Hold
300
– – ﹤0.01% 4312
2025
Q3 		$4.15K Buy
+300
New +$3.71K ﹤0.01% 3925

Other funds holding CVKD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Rockefeller Capital Management's CVKD Position: Q2 2026 in Review

Rockefeller Capital Management held its Cadrenal Therapeutics (CVKD) position steady in Q2 2026 at 150 shares worth $501. The position accounts for ﹤0.01% of the portfolio, ranked #4599.

Rockefeller Capital Management first reported a position in CVKD in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.15K in Q3 2025. 19 funds tracked by Wall St. Rank hold CVKD as of Q2 2026.

  • Rockefeller Capital Management held 150 shares of Cadrenal Therapeutics worth $501 as of Q2 2026.
  • Rockefeller Capital Management left its Cadrenal Therapeutics share count unchanged in Q2 2026.
  • Cadrenal Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4599 holding.
  • Rockefeller Capital Management first reported a position in Cadrenal Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Rockefeller Capital Management's Cadrenal Therapeutics position peaked at $4.15K in Q3 2025.
  • 19 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.